Bausch Health Companies (TSE:BHC) Stock: Insider Mirza Dautbegovic Sells 20,000 Shares

Bausch Health Companies Inc. (TSE:BHC) insider Mirza Dautbegovic sold 20,000 shares of the business’s stock in a transaction on Thursday, October 29th. The shares were sold at an average price of C$11.18, for a total transaction of C$223,600.00. Following the completion of the transaction, the insider directly owned 224,745 shares of the company’s stock, valued at C$2,512,649.10. This trade represents a 8.17% decrease in their position.

Bausch Health Companies Price Performance

BHC opened at C$11.56 on Monday. The company has a quick ratio of 0.58, a current ratio of 1.56 and a debt-to-equity ratio of -1,559.86. Bausch Health Companies Inc. has a 12 month low of C$6.10 and a 12 month high of C$12.65. The company has a fifty day simple moving average of C$8.99 and a 200 day simple moving average of C$7.98. The stock has a market cap of C$4.33 billion, a P/E ratio of -5.12, a P/E/G ratio of 0.21 and a beta of 0.73.

Bausch Health Companies (TSE:BHC) last posted its earnings results on Wednesday, October 28th. The company reported C$2.52 earnings per share for the quarter. Bausch Health Companies had a positive return on equity of 57.67% and a negative net margin of 7.43%. The firm had revenue of C$4.19 billion for the quarter. On average, research analysts expect that Bausch Health Companies Inc. will post 5.55 EPS for the current year.

Bausch Health Companies declared that its Board of Directors has authorized a share buyback plan on Wednesday, October 28th that authorizes the company to buy back C$70 million in outstanding shares. This repurchase authorization authorizes the company to reacquire up to 1.9% of its shares through open market purchases. Share repurchase plans are generally an indication that the company’s board believes its shares are undervalued.

Analyst Upgrades and Downgrades

Separately, Jefferies Financial Group raised shares of Bausch Health Companies to a “hold” rating in a research report on Wednesday, July 22nd. Three investment analysts have rated the stock with a Hold rating. According to data from MarketBeat, the stock presently has an average rating of “Hold”.

About Bausch Health Companies

Bausch Health Companies Inc (NYSE:BHC)(TSX:BHC) is a global diversified pharmaceutical company enriching lives through our relentless drive to deliver better health care outcomes. We develop, manufacture and market a range of products primarily in gastroenterology, hepatology, neuroscience, dermatology, dentistry, aesthetics, international pharmaceuticals and eye health, through our controlling interest in Bausch + Lomb. Our ambition is to be a globally integrated healthcare company, trusted and valued by patients, HCPs, employees and investors.